Related Experiment Videos
Adverse tissue reactions to bioabsorbable fixation devices.
1Department of Orthopaedic and Trauma Surgery, University Hospital, Helsinki, Finland.
Clinical Orthopaedics and Related Research
|February 29, 2000
Summary
Polyglycolic acid implants caused inflammatory reactions in 5.3% of patients, unlike polylactic acid implants. Further research is needed to assess the long-term biocompatibility of polylactic acid in orthopedic surgery.
Area of Science:
- Orthopedic Surgery
- Biomaterials Science
- Inflammatory Response
Background:
- Absorbable fixation devices like pins, rods, bolts, and screws made of polyglycolic acid (PGA) and polylactic acid (PLA) are used in orthopedic procedures.
- Local inflammatory, sterile tissue reactions can occur following the use of these bioresorbable implants.
Purpose of the Study:
- To investigate the incidence, characteristics, and risk factors of adverse tissue reactions associated with polyglycolic acid and polylactic acid orthopedic implants.
- To evaluate the clinical significance and histopathological findings of these reactions.
Main Methods:
- Retrospective analysis of 2528 patients who underwent surgery with PGA or PLA fixation devices.
- Review of clinical records, implant types, indications for use, and patient outcomes.
- Histopathological examination of tissue reactions.
Main Results:
- A total of 108 patients (4.3%) experienced clinically significant local inflammatory reactions.
- Reactions were predominantly associated with polyglycolic acid implants (5.3% incidence) compared to polylactic acid implants (0.2% incidence).
- Risk factors included poorly vascularized bone, quinone dye additives, and large implant surface area (screws).
Conclusions:
- Polyglycolic acid implants demonstrate a higher risk of adverse tissue reactions compared to polylactic acid implants.
- While polylactic acid shows better initial biocompatibility, its long-term effects require further investigation due to slow degradation.
- Identifying risk factors aids in predicting and potentially mitigating adverse tissue responses to bioresorbable orthopedic implants.